FDA advisers vote unanimously in support of over-the-counter birth-control pill

Advisers for the US Food and Drug Administration voted unanimously on Wednesday in support of making the birth-control pill Opill available over-the-counter, saying the benefits outweigh the risks.

Two FDA advisory panels agreed that people would use Opill safely and effectively and said groups such as adolescents and those with limited literacy would be able to take the pill at the same time every day without help from a health care worker.

The advisers were asked to vote on whether people were likely to use the tablet properly so that the benefits would exceed the risks. Seventeen voted yes. Zero voted no or abstained.

Opill manufacturer Perrigo hailed the vote as a "groundbreaking" move for women's health.

"Perrigo is proud to lead the way in making contraception more accessible to women in the U.S.," Murray Kessler, Perrigo's president and CEO, said in a statement. "We are motivated by the millions of people who need easy access to safe and effective contraception."

The FDA doesn't have to follow its advisers' advice, but it often does. It is expected to decide whether to approve the over-the-counter pill this summer.

If it's approved, this will be the first birth-control pill available over the counter in the United States. Opill is a "mini-pill" that uses only the hormone progestin.